Immunovant To Report Financial Results For The Fourth Quarter And Fiscal Year Ended March 31, 2026, And Provide Business Update On Wednesday, May 20, 2026

2026-05-11 04:18:17

(MENAFN- GlobeNewsWire - Nasdaq) DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under“News & Events” in the Investors section of the Immunovant website at . The archived webcast will be available on Immunovant's website after the conference call.

About Immunovant

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.

Contacts:

Investors

Keyur Parekh

...

Media

Stephanie Lee

...

MENAFN11052026004107003653ID1111099234

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.